Stephen Bushnell, Featured at GTC's Translational Medicine Meeting, Oct. 24th-26th, Philadelphia

Monrovia, California (PressExposure) September 19, 2012 -- Stephen Bushnell will give a featured presentation on 'Patient Stratification in Multiple Sclerosis: The Search Continues - An Update From the Pursuit of Serum Protein Biomarkers' at GTC's 4th Translational Medicine conference (October 24th-26th, 2012 in Philadelphia, PA)

Relapsing Remitting Multiple Sclerosis (RRMS) is a chronic inflammatory disease which targets the central nervous system. Despite a growing number of approved disease modifying therapies with different mechanisms of action, there is a varied therapeutic response in RRMS patients and an acute need for biomarkers that will identify patients who will respond favorably to therapies either prior to treatment or within a short period on therapy. Inflammatory proteins including cytokines and chemokines have been shown to be dysregulated in a number of MS subtypes and are linked to pathogenesis. Given the close link between serum proteins and disease state, there is the potential that disease related protein markers could be candidate biomarkers of pharmacologic and therapeutic response. This talk will focus on the application of retrospective analysis of banked serum samples from clinical studies to discover new and validate emerging serum protein biomarkers associated with therapeutic response. It will review phenotypic selection of subjects, approaches to sample qualification, and recent results in the attempt to validate IL17-F as a possible predictor of non-response to IFNbeta-1a. It will also review critical success factors for patient stratification efforts in autoimmune diseases.

Dr Bushnell is responsible for the Patient Stratification and Translational Research Group. In this role, he is responsible for leading scientific studies to discover and validate predictive and prognostic disease markers with a focus on molecular markers for Multiple Sclerosis. Prior to this role he was Sr. Director of portfolio management at Biogen covering ~ 50 R&D programs at various phases in drug discovery and development. Dr. Bushnell was the Site Head of the Sanofi Aventis Cambridge Genomics Center where he had scientific responsibility for the application of genomics technologies to target and biomarker discovery, and compound mechanism of action studies. He also worked in R&D at Ciba Corning Diagnostics (now Bayer Diagnostics) on nucleic acid diagnostic tests and biomarker discovery in Oncology. He holds a Ph.D. in Materials Science and Engineering from Northeastern University, and holds patents and papers in a variety of areas including biomarker discovery in multiple sclerosis, computational approaches in transcript profiling, and methods in nucleic acid diagnostics.

The 4th Translation Medicine Conference is part of our 8th Modern Drug Discovery & Development Summit. Other tracks for this summit include:

8th Modern Drug Discovery & Development Summit
(Day 1, Oct 24, 2012) - Plenary Keynote Session
(Day 2-3, Oct 25-26, 2012) - Breakout Tracks:
7th Assay & Drug Discovery Technologies
9th Stem Cell Research & Therapeutics
3rd Pharmacokinetics & Pharmacodynamics
Biotechnology Transfer & Commercialization

For more information, please visit http://www.gtcbio.com/tmed

About GTC

GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.


GTC (Global Technology Community), LLC, is a privately held company founded in 2002.

Press Release Source: http://PressExposure.com/PR/GTC.html

Press Release Submitted On: September 20, 2012 at 7:53 pm
This article has been viewed 31787 time(s).